Stella-Jones Insiders Placed Bullish Bets Worth CA$1.07m
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Stella-Jones Inc. (TSE:SJ), that sends out a positive message to the company's shareholders.
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
Over the last year, we can see that the biggest insider sale was by the insider, James Manzi, for CA$464k worth of shares, at about CA$92.79 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is CA$77.59. So it may not shed much light on insider confidence at current levels. James Manzi was the only individual insider to sell shares in the last twelve months.
Over the last year, we can see that insiders have bought 15.17k shares worth CA$1.1m. But insiders sold 11.00k shares worth CA$955k. Overall, Stella-Jones insiders were net buyers during the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
See our latest analysis for Stella-Jones
Stella-Jones is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
The last three months saw some Stella-Jones insider selling. insider James Manzi divested only CA$66k worth of shares in that time. It's not great to see insider selling, nor the lack of recent buyers. But the volume sold is so low that it really doesn't bother us.
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 0.2% of Stella-Jones shares, worth about CA$7.2m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.
An insider hasn't bought Stella-Jones stock in the last three months, but there was some selling. On the other hand, the insider transactions over the last year are encouraging. Still, insiders don't own a great deal of the stock. So we can't be sure that insiders are optimistic. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Stella-Jones. For example, Stella-Jones has 2 warning signs (and 1 which is a bit unpleasant) we think you should know about.
Of course Stella-Jones may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Washington Post
an hour ago
- Washington Post
Dave's Hot Chicken sold to Subway owner Roark Capital in a $1 billion deal
Dave's Hot Chicken said Monday it has been acquired by the private equity firm Roark Capital in a deal valued at $1 billion. Dave's Hot Chicken got its start in 2017 as a popup in a Los Angeles parking lot. It has grown exponentially since then and expects to end this year with 400 restaurants worldwide. The brand specializes in Nashville-style hot chicken. Investors in Dave's Hot Chicken have included the rapper Drake, who gives away hot chicken sliders every year on Oct. 24, his birthday. Atlanta-based Roark specializes in franchised businesses. It bought the Subway sandwich chain in 2023 and backs two holding companies that own multiple restaurant chains: Inspire Brands, the parent of Arby's, Dunkin', Jimmy John's, Sonic and Buffalo Wild Wings; and GoTo Foods, which owns Auntie Anne's, Carvel, Cinnabon and Jamba. Dave's Hot Chicken said its leadership team — including CEO Bill Phelps and the four childhood friends who founded the company — will remain and continue to lead menu innovation, food quality, operations and marketing. 'Our entire organization is excited about the fit between Dave's Hot Chicken and Roark, and we're looking forward to continuing to blow our guests' minds and unlocking growth and value for our franchise partners,' Phelps said in a statement.

Wall Street Journal
an hour ago
- Wall Street Journal
How Moderna Went From Pandemic Hero to Vaccine Victim
Moderna MRNA 1.84%increase; green up pointing triangle was once a darling of the first Trump administration, which went to great lengths to help the company develop its Covid-19 vaccine that protected millions of people from the virus. Now the biotech is caught in the crossfire of Trump 2.0 as vaccine-making comes under fire. In the latest setback for Moderna MRNA 1.84%increase; green up pointing triangle, the Food and Drug Administration on Friday approved its next-generation Covid shot for a narrower population of patients than the company intended. The approval grants use of the vaccine only in older adults and people aged 12 to 64 with health risks.


Bloomberg
an hour ago
- Bloomberg
Big Take: A Turning Point in Trump's Trade War
We're more than halfway through the 90-day pause on President Trump's sweeping reciprocal tariffs. That three-month delay was supposed to give the US time to negotiate trade deals with countries around the world. And while talks are ongoing, many deals still seem out of reach. Now, legal challenges to Trump's tariff strategy have thrown another wrench in the administration's plans. On today's Big Take podcast, host Sarah Holder sits down with Bloomberg's Brendan Murray to hear a status report on the latest steel tariff hikes and trade negotiations, and with legal reporter Erik Larson to explore how the courts could upend Trump's agenda.